Treatment Information

Back

Breast Cancer treatment details. Biologic therapy.

Oncologisch Centrum Sint-Augustinus, Wilrijk, Belgium.

Survival: monthsCountry:Belgium
Toxiciy Grade:3City/State/Province:Wilrijk
Treatments:Biologic therapyHospital:Oncologisch Centrum Sint-Augustinus
Drugs:Journal:Link
Date:Mar 2008

Description:

Patients: This phase II study involved 111 women with advanced, hormone-sensitive breast cancer. The median age was 56 years, ranging from 28 to 82.

Treatment: Patients were treated with the biological therapies exemestane and celecoxib, or exemestane alone.

Toxicity: Grade 3 venous thrombosis, congestive heart failure, and hypersensitivity were reported. The most common toxicity was grade 2 hot flushes.

Results: The median overall survival of these women was 17 months; 73.9 weeks for those treated with exemestane and celecoxib, and 74.1 weeks for those treated with exemestane only.

Support: This study was supported by Pfizer Inc., which markets exemestane as Aromasin®.

Correspondence: Dr. Luc Y. Dirix





Back